If you are trying to understand what is hexarelin, the short answer is that it is a synthetic growth-hormone-releasing peptide (GHRP) that scientists have used as a laboratory tool for studying how the body regulates growth hormone. It belongs to a broader family of compounds known as growth hormone secretagogues, and it has been the subject of both endocrine and cardiovascular research since the 1990s. This article summarizes what peer-reviewed and preclinical studies have investigated, framed strictly for scientific and educational context.
What Is Hexarelin? Chemistry and Classification
Hexarelin (also catalogued under the name examorelin) is a synthetic hexapeptide, meaning it is built from six amino acids. In the ChEMBL database it is recorded as CHEMBL108335 with the molecular formula C47H58N12O6 and a molecular weight of roughly 887 g/mol. Its sequence is a modified derivative of an earlier research peptide, GHRP-6, engineered for greater chemical stability. Because it is a small peptide rather than a small-molecule drug, its physical properties differ substantially from orally optimized pharmaceuticals.
Within the growth hormone secretagogue class, hexarelin is frequently studied alongside its natural analog, ghrelin. Both interact with the same primary receptor system, but researchers have noted that hexarelin is chemically more stable and, in some experimental systems, functionally more potent than ghrelin as a growth-hormone-releasing agent.
Receptor Targets Studied in the Literature
The most studied mechanism of hexarelin involves the growth hormone secretagogue receptor (GHS-R), the same receptor activated by ghrelin. Activation of this receptor in the pituitary is associated with pulsatile release of growth hormone in experimental models. A distinguishing feature that has drawn research attention is that hexarelin also binds a second receptor: the scavenger receptor CD36, which is expressed in cardiac tissue and macrophages.
This dual-receptor profile is central to much of the peptide’s research literature. In one mechanistic study, hexarelin binding to CD36 and the ghrelin receptor was linked to upregulation of sterol transporters and cholesterol efflux in macrophages through a PPAR-gamma-dependent pathway, with the authors reporting reduced atherosclerotic lesions in a mouse model (Avallone et al., 2006). It is important to read such findings as descriptions of investigated biological pathways in laboratory systems, not as established outcomes in humans.
Endocrine Research Findings
Early human endocrine studies characterized how hexarelin influences pituitary hormone secretion. One controlled clinical study examined the interaction between hexarelin and somatostatin, reporting that the two counteract each other’s stimulatory and inhibitory effects on growth hormone secretion, and that hexarelin combined with growth-hormone-releasing hormone produced a synergistic response (Massoud et al., 1997). Separate work investigated hexarelin’s effect on prolactin, finding that its prolactin-releasing activity was preserved in patients with acromegaly but blunted in those with pathological hyperprolactinemia (Ciccarelli et al., 1996).
A broader review of growth hormone secretagogues noted that this class promotes growth hormone release subject to the body’s own negative feedback, which the authors framed as a potential advantage over exogenous growth hormone in experimental settings. That same review emphasized that few long-term, rigorously controlled studies exist, and it flagged open questions around glucose metabolism and insulin sensitivity (Sigalos & Pastuszak, 2018). The evidence base, in other words, remains limited and preliminary.
Cardiovascular Research in Preclinical Models
A significant portion of hexarelin research has focused on the heart, largely because of its CD36 binding. A review of the cardiovascular action of hexarelin summarized evidence that the peptide may have direct cardiac effects beyond growth hormone release, mediated in part through cardiac CD36 (Mao et al., 2014).
Several of the underlying studies were conducted in animal models. In hypophysectomized rats, hexarelin was reported to reduce ischemia-reperfusion damage, and the authors concluded the effect was growth-hormone-independent because a related peptide that does not bind cardiac tissue was ineffective (Locatelli et al., 1999). In a mouse myocardial infarction model, a single oral dose of hexarelin was associated with preserved chronic cardiac function on measures such as ejection fraction (Mao et al., 2014). Additional cell-based work has examined hexarelin’s relationship to autophagy in cardiomyocytes subjected to experimental hypertrophy. These are preclinical, hypothesis-generating results; they have not been established in controlled human trials, and animal findings frequently do not translate.
Reading the Evidence Responsibly
Hexarelin sits at an intersection of endocrine and cardiovascular research, and its dual GHS-R and CD36 activity is what makes it scientifically interesting as a probe compound. At the same time, the literature is dominated by mechanistic and animal studies, with only small early-phase human endocrine work. Understanding what the science has actually investigated, versus what it has proven, is essential before drawing any conclusions. Where you see claims of definitive benefit, the underlying evidence is almost always preliminary.
References
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018. DOI: 10.1016/j.sxmr.2017.02.004
- Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014. DOI: 10.11909/j.issn.1671-5411.2014.03.007
- Avallone R, et al. A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in macrophages through a PPAR-gamma-dependent pathway. Mol Endocrinol. 2006. DOI: 10.1210/me.2006-0146
- Mao Y, et al. One dose of oral hexarelin protects chronic cardiac function after myocardial infarction. Peptides. 2014. DOI: 10.1016/j.peptides.2014.04.004
- Locatelli V, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999. DOI: 10.1210/endo.140.9.6948
- Massoud AF, Hindmarsh PC, Brook CG. Interaction of the growth hormone releasing peptide hexarelin with somatostatin. Clin Endocrinol (Oxf). 1997. DOI: 10.1046/j.1365-2265.1997.3121128.x
- Ciccarelli E, et al. Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients. Clin Endocrinol (Oxf). 1996. DOI: 10.1046/j.1365-2265.1996.626446.x
- ChEMBL Database (EMBL-EBI). Hexarelin / Examorelin, CHEMBL108335. ChEMBL compound record
Research Use Only. Hexarelin is a research compound intended solely for laboratory and scientific investigation. It is not a drug, dietary supplement, or medical product, and it is not intended for human or animal consumption, diagnosis, treatment, or the prevention of any disease. This article is educational and describes only what published research has examined; nothing here constitutes medical advice or a health claim. Statements referenced from PubMed-indexed literature are attributed to their original authors via the DOIs listed above.